] . The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: A prospective population-level analysis. PLoS Med. 2019;16(4):e1002783. 
(864.32 KB)
(864.32 KB). Place-specific factors associated with adverse maternal and perinatal outcomes in Southern Mozambique: a retrospective cohort study. BMJ Open. 2019;9(2):e024042. (2.94 MB)
(2.94 MB). Protocol 13PRT/9313:The Community Level Interventions for Pre-eclampsia (CLIP) Trials: four prospective cluster randomised controlled trials comparing a package of interventions directed towards improving maternal and perinatal outcomes related to pre-ecl [Internet]. 2019 . https://clinicaltrials.gov/ct2/show/study/NCT01911494?term=01911494&rank=1
. Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia. Pregnancy Hypertens. 2019;15:42-50. (887.01 KB)
(887.01 KB). Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia. Hypertension. 2018;71(4):659-665. (237.99 KB)
(237.99 KB). CHIPS-Child: Testing the developmental programming hypothesis in the offspring of the CHIPS trial. Pregnancy Hypertens. 2018;14:15-22. (1011.52 KB)
(1011.52 KB). A comparison of maternal and newborn health services costs in Sindh Pakistan. PLoS One. 2018;13(12):e0208299. (645.08 KB)
(645.08 KB). Development and internal validation of the multivariable CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate of Risk) clinical risk prediction model. Crit Care. 2018;22(1):278. (961.71 KB)
(961.71 KB). Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique. Pregnancy Hypertens. 2018;11:26-31. (374.54 KB)
(374.54 KB). Influence of Gestational Age at Initiation of Antihypertensive Therapy: Secondary Analysis of CHIPS Trial Data (Control of Hypertension in Pregnancy Study). Hypertension. 2018;71(6):1170-1177. (303.94 KB)
(303.94 KB). MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)-implementation of a national guideline in Canada. Implement Sci. 2018;13(1):8. (1.89 MB)
(1.89 MB). Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertens. 2018;11:115-123. (501.41 KB)
(501.41 KB). Diagnostic Performance of Placental Growth Factor in Women With Suspected Preeclampsia Attending Antenatal Facilities in Maputo, Mozambique. Hypertension. 2017;69(3):469-474. (378.99 KB)
(378.99 KB). External Validation of the fullPIERS Model for Predicting Adverse Maternal Outcomes in Pregnancy Hypertension in Low- and Middle-Income Countries. Hypertension. 2017;69(4):705-711. (149.83 KB)
(149.83 KB). Maternal and Newborn Health in Karnataka State, India: The Community Level Interventions for Pre-Eclampsia (CLIP) Trial's Baseline Study Results. PLoS One. 2017;12(1):e0166623. (2.12 MB)
(2.12 MB). Multiple Organ Dysfunction Score Is Superior to the Obstetric-Specific Sepsis in Obstetrics Score in Predicting Mortality in Septic Obstetric Patients. Crit Care Med. 2017;45(1):e49-e57. (910.16 KB)
(910.16 KB). Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237. (986.49 KB)
(986.49 KB). A process evaluation plan for assessing a complex community-based maternal health intervention in Ogun State, Nigeria. BMC Health Serv Res. 2017;17(1):238. (925.17 KB)
(925.17 KB). Reverse innovation in maternal health. Obstet Med. 2017;10(3):113-119. (710.03 KB)
(710.03 KB). Seasonal variation in geographical access to maternal health services in regions of southern Mozambique. Int J Health Geogr. 2017;16(1):1. (9.27 MB)
(9.27 MB). SOCIETAL PERSPECTIVE ON COST DRIVERS FOR HEALTH TECHNOLOGY ASSESSMENT IN SINDH, PAKISTAN. Int J Technol Assess Health Care. 2017;33(2):192-198. (266.82 KB)
(266.82 KB). Validating the Performance of the Modified Early Obstetric Warning System Multivariable Model to Predict Maternal Intensive Care Unit Admission. J Obstet Gynaecol Can. 2017;39(9):728-733.e3. (176.34 KB)
(176.34 KB). Visual or automated dipstick testing for proteinuria in pregnancy?. Pregnancy Hypertens. 2017;7:50-53. (234.13 KB)
(234.13 KB). Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. Acta Obstet Gynecol Scand. 2016;95(7):763-76. (803.67 KB)
(803.67 KB). The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?. Hypertension. 2016;68(5):1153-1159. (476.19 KB)
(476.19 KB). Community perspectives on the determinants of maternal health in rural southern Mozambique: a qualitative study. Reprod Health. 2016;13(Suppl 2):112. (1019.85 KB)
(1019.85 KB). Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?. BJOG. 2016;123(7):1135-41. (144.71 KB)
(144.71 KB). The Cost Implications of Less Tight Versus Tight Control of Hypertension in Pregnancy (CHIPS Trial). Hypertension. 2016;68(4):1049-55. (470.91 KB)
(470.91 KB). Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG. 2016;123(7):1143-51. (153.93 KB)
(153.93 KB). Fetal, Infant and Maternal Outcomes among Women with Prolapsed Membranes Admitted before 29 Weeks Gestation. PLoS One. 2016;11(12):e0168285. (862.28 KB)
(862.28 KB). Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes. J Obstet Gynaecol Can. 2016;38(10):936-944.e3. (667.48 KB)
(667.48 KB). Obstetric medical care in Canada. Obstet Med. 2016;9(3):117-9. (81.97 KB)
(81.97 KB). Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016;42:1-8. (475.29 KB)
(475.29 KB). Pre-eclampsia. Lancet. 2016;387(10022):999-1011. (128.83 KB)
(128.83 KB). Preventing deaths due to the hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;36:83-102. (389.82 KB)
(389.82 KB). A protocol for developing, disseminating, and implementing a core outcome set for pre-eclampsia. Pregnancy Hypertens. 2016;6(4):274-278. (336.66 KB)
(336.66 KB). The Usefulness of the APACHE II Score in Obstetric Critical Care: A Structured Review. J Obstet Gynaecol Can. 2016;38(10):909-918. (304.95 KB)
(304.95 KB). Women's views and postpartum follow-up in the CHIPS Trial (Control of Hypertension in Pregnancy Study). Eur J Obstet Gynecol Reprod Biol. 2016;206:105-113. (412.73 KB)
(412.73 KB). Assessing the incremental value of blood oxygen saturation (SpO(2)) in the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Risk Prediction Model. J Obstet Gynaecol Can. 2015;37(1):16-24. (1.11 MB)
(1.11 MB). Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens. 2015;5(4):315-21. (505.41 KB)
(505.41 KB). Economic evaluation of Community Level Interventions for Pre-eclampsia (CLIP) in South Asian and African countries: a study protocol. Implement Sci. 2015;10:76. (1.88 MB)
(1.88 MB). The hypertensive disorders of pregnancy (29.3). Best Pract Res Clin Obstet Gynaecol. 2015;29(5):643-57. (227.04 KB)
(227.04 KB). Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015;14(3):453-61. (463.16 KB)
(463.16 KB). Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(24):2367-8. (515.75 KB)
(515.75 KB). Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres. J Obstet Gynaecol Can. 2015;37(11):975-87. (362.1 KB)
(362.1 KB). Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. BMC Pregnancy Childbirth. 2015;15:347. (549.75 KB)
(549.75 KB). Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT. Int J Gynaecol Obstet. 2015;131 Suppl 1:S10-5. (662.6 KB)
(662.6 KB). 34 weeks of gestation-lost in translation. J Obstet Gynaecol Can. 2014;36(6):480-481. (706.24 KB)
(706.24 KB). Effect of magnesium sulphate on fetal heart rate parameters: a systematic review. J Obstet Gynaecol Can. 2014;36(12):1055-1064. (1.57 MB)
(1.57 MB). Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One. 2014;9(12):e113715. (359.44 KB)
(359.44 KB)